N-Acetylcysteine and Atherosclerosis: Promises and Challenges

Area of Science:

• Cardiovascular Science
• Pharmacology
• Biochemistry

Background:

• Atherosclerosis is a major cause of cardiovascular disease, driven by complex mechanisms involving inflammation and oxidative stress.
• N-acetylcysteine (NAC) is a known mucolytic and antidote with a strong safety profile.
• NAC exhibits antioxidant and anti-inflammatory effects by boosting glutathione and inhibiting inflammatory cytokines.

Purpose of the Study:

• To review preclinical and clinical data on N-acetylcysteine's effects on atherosclerosis.
• To explore NAC's mechanisms of action in atherosclerosis.
• To identify challenges in current research.

Main Methods:

• Systematic review of animal studies on NAC and atherosclerosis.
• Analysis of clinical trial data investigating NAC in atherosclerosis patients.
• Examination of molecular pathways involved in NAC's effects.

Main Results:

• Animal studies consistently show NAC reduces atherosclerosis development and progression.
• Clinical study data on NAC's efficacy in atherosclerosis patients is limited and shows inconsistent outcomes.
• NAC's mechanisms involve increasing glutathione and reducing inflammatory mediators.

Conclusions:

• NAC demonstrates significant potential in preclinical models of atherosclerosis.
• Further well-designed clinical trials are needed to confirm NAC's efficacy and optimal use in patients with atherosclerosis.
• Understanding NAC's clinical impact requires addressing current research limitations.